Unregulated stem cell therapy A Frankenstein monster in the absence of effective laws
Satish K Gupta, Partner, Rautray and Co Law Firm and Dr BM Gandhi, Chief Executive Officer, Neo BioMed Services, Former Advisor,…
Sign in
Sign in
Recover your password.
A password will be e-mailed to you.
Browsing Category
Management
’If we need to be competitive in the global marketplace, we have to adopt biotech…
Novozymes, the world’s leader in bioindustrial solutions recently announced, the BioAg alliance, along with Monsanto to transform…
‘In all of Asia, the focus on intangible capital is much underdeveloped as compared to mature…
It is not just the physical assets but the intangible assets which help in realising the success of an M&A, rarely considered…
’Current financing climate unable to support large vision models’
A promising biotechnology start up that attracted investors in the initial stages, Avesthagen today finds itself in a funding…
‘When regulation becomes ill-defined and ambiguous, all industry players suffer’
With an established clinical genomics practice in India.Covering over 20 hospitals around the country, Strand Life Sciences…
‘Use of enzymes in API manufacture produces a diverse range of cost savings’
Incorporating biocatalysis within the API manufacturing process can aid Indian manufacturers increase global market share by…
Vision 2025 for Indian bioagri sector
In a recent released report, Indian Biotech Agriculture Industry:Vision 2025, CII and Accenture attempt to define the industry’s…
Pharma market posts 14 per cent growth in November 2013: IMS
MAT market growth for the industry continued to be below the 10 per cent mark, for the third successive month, in November
Plagiarism, research publications and law
Raghvendralal Saha, Former Director, Patent Facilitating Centre, Technology Information, Forecasting and Assessment Council,…
Leveraging the OTC potential of India’s 350 million Kidsumers
Valued at $409 million in 2012, the children’s OCT market remains an untapped opportunity in India. Sreedevi Yallamrazu, Manager –…
Time for an alternative patent system?
Do developing nations need an alternative patent system? Viveka Roychowdhury presents two diametrically opposing views on this…
Redefining CSR
Companies Bill 2012’s two per cent mandate for CSR has evoked mixed reviews from the pharma industry. Some have welcomed the move,…
It is high time that CCI takes steps to curb anti-competitive settlements
MM Sharma, Head-Competition Law and Policy, Vaish Associates Advocates speaks to Usha Sharma about the strategy
Bribery and corruption in public procurement in India: A unique approach
Arpinder Singh, Partner & National Leader – Fraud Investigation and Dispute Services, EY (India) and Rajiv Joshi, Director –…
Fixing India’s TB control policy
Despite having a focused TB control programme for over five decades, India faces the ignominy of having the largest number of TB…
Time for reflection and implementation
Kirit S Javali, Partner, Jafa & Javali highlights the need for policies to address concerns, while ensuring affordability and…
Regulations must be implementable, practical
Dr Sauren Das, Executive Director, Excel Life Sciences suggests that while framing regulations, regulators should handpick the bad…
Urgently require systematic investment in infrastructure enhancements
The Government of India is in a perfect position to provide direction and support to meet the urgent unmet needs of the 70+…
Strategies for making high pharma quality affordable
Ajaz S Hussain, Former Deputy Director Office of Pharmaceutical Science at the US FDA and currently the Founder of Insight, Advice…
Ethical behaviour will drive success
Ranjit Shahani, Vice Chairman and Managing Director, Novartis India elucidates about India’s pharmaceutical sector, which is going…